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Background: To investigate the clinical feature and the local failure patterns after intensity-modulated radiotherapy
for nasopharyngeal carcinoma.
Methods: Between March 2007 and July 2009, 710 patients with nasopharyngeal carcinoma were treated with
intensity-modulated radiotherapy. The magnetic resonance imagings obtained at recurrence were registered with
the original planning computed tomography for dosimetry analysis.
Results: With a median follow-up of 38 months, 34 patients have developed local recurrence (32 cases valid). The
incidence of invasion to nasopharynx, parapharyngeal space and the retropharyngeal space by the primary tumors
was 100%, 75.0% and 62.5%, respectively, but 78.1%, 34.4% and 21.9% at recurrence, respectively. The rate of inva-
sion to ethmoid sinus was 3.1% by the primary tumors but 28.1% at recurrence (p = 0.005). The topographic analysis
of the local failure patterns showed “central” in 16 patients; “marginal” in 9; and “outside” in 7. The median volumes
of primary gross tumor were 45.84 cm3 in the central failure group, 29.44 cm3 in the marginal failure group, and
21.52 cm3 in the outside failure group, respectively(p = 0.012), and the median volumes of primary clinical target1
were 87.28 cm3, 61.90 cm3 and 58.74 cm3 in the three groups, respectively (p = 0.033).
Conclusions: In patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy, the recur-
rent tumors had their unique characteristic and regularity of invasion to adjacent structures. “Central” failure was the
major local failure pattern. The volumes of primary gross tumor and clinical target1 were significantly correlated
with recurrent patterns. Employ more aggressive approaches to tumor cells which will be insensitive to radiotherapy
may be an effective way to reduce the central failure.
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Treatment failureBackground
Nasopharyngeal carcinoma (NPC) has a distinct epidemi-
ology compared with other head and neck squamous cell
carcinomas. Standard treatment for NPC is radiotherapy
(RT) for early-stage lesions or chemoradiotherapy for
more advanced diseases. However, local-regional relapse
after conventional RT remains one of the major treatment
failures. In researches with optimized conventional RT
and a more frequent use of chemotherapy in the 1990s,* Correspondence: taixianglu@126.com
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unless otherwise stated.the 5-year local-regional failure rate of 15.0%-19.1% has
been reported [1-3]. Studies have shown that the radiation
dose delivered to the target volume correlates strongly
with local disease control [4]. However, dose escalation by
conventional technique is limited by the tolerance of adja-
cent critical organs.
Intensity-modulated radiotherapy (IMRT) is a major
breakthrough in the treatment of NPC. By conforming
the doses to the irregularly shaped tumor, dose escal-
ation is possible with IMRT, which can potentially lead
to improvement in local control [5,6]. Early treatment
outcome was encouraging and conformed the promising
role of IMRT [7]. Series with longer follow-up have alsohis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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regional control exceeded 90% in both early stage and
advanced NPC [8,9].
However, it is critical to examine the patterns of recur-
rence after IMRT, since one must consider the potential
that: (1) the image-based target definitions used in
IMRT might lead to smaller target volumes; (2) the con-
formal treatment plans and radiation delivery techniques
that are used to minimize the dose to adjacent normal
tissues might potentially increase the risk of marginal
miss. The present study investigates the regularity of
recurrent tumor invading to adjacent structures and
make a detailed analysis to the dosimetric relationship
between the patterns of failure and the initial irradiated
dose of the recurrent site, which may provide informa-
tion that is helpful in the future target volume defin-
ition and margin choices.
Methods
Patient selection
Between March 2007 and July 2009, 710 non-metastatic
NPC patients were treated with IMRT at the Cancer
Center of Sun Yat-sen University. The male/female ratio
was nearly 3.2:1, and age ranged from 19 to 78 years
(median, 45 years). All patients underwent disease sta-
ging according to the UICC 2009 staging system [10]. A
total of 29 patients were in stage I; 92 in stage II; 390 in
stage III; and 199 in stage IVa-b. T-classification was as
follows: T1: 89; T2: 127; T3: 329; and T4: 165.
Radiotherapy
Patients were immobilized in the supine treatment pos-
ition by a thermoplastic head and shoulder device. The
CT images were obtained and transferred to the
treatment-planning system, an inverse planning system
(CORVUS 3.0/3.2, Peacock plan) developed by NOMOS
Corporation.
Target volumes and normal tissues were delineated
out on each slice. The gross tumor volume (GTV) in-
cluded the primary nasopharyngeal tumor (GTVnx) and
involved lymph nodes (GTVnd) as shown by clinical,
endoscopic, and radiologic findings. For patients given
induction chemotherapy, the targets were based on the
post-chemotherapy extent as shown on the MRI images.
Two clinical target volumes (CTVs) were delineated.
CTV1 was defined as the GTVnx plus a 5-10 mm margin
to encompass the high-risk sites of microscopic extension,
including the entire nasopharynx mucosa plus a 5 mm
submucosal volume. CTV2 was defined as the CTV1 plus
a 5-10 mm margin (3–5 mm margin posteriorly) to en-
compass the low-risk sites of microscopic extension (in-
cluding the parapharyngeal spaces, posterior third of nasal
cavities and maxillary sinuses, pterygoid processes, ptery-
goid fossae, base of skull, lower half of sphenoid sinus,anterior half of clivus, and petrous apex), and lymphatic
regions (the retropharyngeal lymph nodal regions, bilat-
eral levels II, III, and Va were routinely covered in all pa-
tients, whereas ipsilateral levels IV, Vb, or supraclavicular
fossae were also included for patients whose positive
lymph nodes located lower than level II). Planning target
volumes (PTVs) for all GTVs and CTVs were generated
automatically according to the immobilization and
localization uncertainties.
The prescribed dose was 68Gy to the PTVnx, 60Gy to
the PTV1, 54Gy to the PTV2, and 64-66Gy to the PTVnd
in 30 fractions. All patients were treated with one fraction
daily over 5 days per week. The whole process of IMRT
was carried out according to an institutional treatment
protocol previously described [11]. The actual dose distri-
butions for the treatment targets are listed in Table 1.
Chemotherapy
Our institutional guidelines recommended IMRT alone
for patients in stage I-II, and IMRT combined with con-
current chemotherapy for those in stage III-IVb. Neoad-
juvant cisplatin-based chemotherapy was applied in
those patients with bulky neck node (>3 cm), and adju-
vant chemotherapy was used for those patients with re-
sidual disease after IMRT.
Follow-up and statistical analysis
After IMRT completion, the patients were subsequently
followed up monthly in the first 3 month, every 3 months
through the first 3 years, then annually. During every
follow-up visit, disease status and treatment toxicity were
assessed. MRI was ordered on a regular basis and as clinic-
ally indicated. All recurrence scans were reviewed by the
experienced radiologists and radiation oncologists. Patients
who had complete response but developed recurrence at
the primary site more than 6 months following completion
of radical radiotherapy with or without chemotherapy were
identified as having a recurrence. All analyses were per-
formed in SPSS 16.0. All statistical tests were two-sided,
and p < 0.05 was considered as statistical significance.
Dataset registration
As has been described before [12,13], the MRI images
obtained at the time when recurrence was diagnosed
were input into the planning system, and each scan
study became a dataset, which was a geometrically self-
consistent set of image data. The initial CT dataset
served as the basis for all the registrations, meaning
that the MRI datasets were moved so they were regis-
tered with the initial CT geometry. Bony, vascular, and
muscular structures in proximity to the failure were
used to guide the co-registration process. This process
was continued until satisfactory visual agreement was
obtained between the MRI surfaces and CT images.
Table 1 Prescription dose to target volumes and dose-volume statistics









GTVnx 68 0.18 65.57 81.24 74.82 33.62
CTV1 60 0.33 55.67 79.88 70.35 68.25
CTV2 54 2.07 39.25 78.21 63.52 322.97
GTVnd(L) 60-64 0.00 62.01 72.20 68.46 4.98
GTVnd(R) 60-64 0.00 61.95 72.15 68.02 5.96
Abbreviations: GTVnx primary nasopharyngeal gross tumor volume, CTV clinical target volume, GTVnd(L) GTV for the involved left cervical lymph nodes, GTVnd(R)
GTV for the involved right cervical lymph nodes.
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The gross recurrent tumor volume (GTVr) was identified
on MRI images while recurrence and transferred to the
original planning CT. Further more, according to the rela-
tionship between GTVr and target volumes of the initial
disease, TG (the intersection of GTVr and GTVnx), TC1
(the intersection of GTVr and CTV1, excluding TG), TC2
(the intersection of GTVr and CTV2, excluding TG and
TC1) and TE (GTVr that outside the range of CTV2)
were also delineated out (Figure 1), which represent recur-
rence in the center of the target, high-dose region, low-
dose region and outside the target respectively.
Doses delivered to the recurrence volumes were calcu-
lated (Figure 2). Analysis of the recurrence patterns with
respect to the dose distribution was initially performed
by evaluating the median minimal dose, maximal dose
and mean dose of GTVr, TG, TC1, TC2, TE, respectively.
The percentages of the GTVr that TG, TC1, TC2 and
TE accounted for were also calculated.
Three different categories were chosen for a sorting of
local failure patterns:
Central: ≥50% of GTVr was within primary GTV (TG
≥50% of GTVr).
Marginal: ≥50% of GTVr was inside primary CTV but
outside primary GTV (TC1 + TC2 ≥ 50% of GTVr).Figure 1 Delineation of target volumes. (a) The gross recurrent tumor v
transferred to the original planning CT. Red line is gross tumor volume (GT




After a median duration of 38 months (range, 6–
59 months), 34 patients have developed local recurrence.
In these patients, the male:female ratio was 3.6:1 and the
median age was 41.5 years (range: 30–61 years). The me-
dian duration from the end of the primary treatment to
the diagnosis of recurrence was 24.0 months (range: 9.0-
37.0 months). Twenty-five patients had biopsy-proven
recurrence, all of which were WHO III. The remaining 9
were diagnosed based on progressive symptoms associ-
ated with new image findings that would explain the
symptoms, of which 4 with MRI and 5 with MRI to-
gether with [18F]fluorodeoxyglucose positron emission
tomography scan. The usual condition was the patients
with tumor over deep submucosa, basilar skull or intra-
cranial area adjacent to the critical structures that might
have technique difficulty or high morbidity probability
for biopsy.
Among the 34 patients, the original IMRT plans of two
patients were lost. Therefore, we concentrated our re-
search on the remaining 32 patients. The median volume
of GTVnx was 33.23 cm3, ranging from 6.08 to 91.43 cm3.olume (GTVr) was identified on MRI images. (b) The GTVr was
V); yellow line, CTV1; blue line, CTV2. (c) Cyan line, TG; orange line, TC1;
Figure 2 Dose delivered to the recurrent site in primary treatment.
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were 74.82Gy, 70.50Gy and 63.52Gy, respectively.
The recurrent disease was Stage I in 4 (12.5%), Stage II
in 3 (9.4%), Stage III in 11 (34.4%), Stage IVa in 12
(37.5%), Stage IVb in 1 (3.1%), and Stage IVc in 1 (3.1%)
patients. A correlation between the T-stages at initial
diagnosis and at recurrence (rT) was shown in Table 2.
Twelve patients had the same T-stages at both diagnoses.
Fifteen patients’ recurrent T-stages were more advanced
than the primaries’, while 5 patients’ primary T-stages
were more advanced than the recurrence’s (p = 0.064).
For further study, sites of primary and recurrent tumor
invasion were compared by McNemar test (Table 3).
The results showed that the invasion rates of the naso-
pharynx, parapharyngeal space and the retropharyngeal
space by the recurrent tumor were significantly lower
than those at primary. Conversely, the invasion rate of
the ethmoid sinus was significantly higher at recurrence.
As the recurrent tumor volumes were contoured
within the planning system, the median mean doses of
GTVr, TG, TC1, TC2 and TE were 70.86Gy, 75.00Gy,
71.27Gy, 64.39Gy and 38.10Gy, respectively, and the me-
dian mean volumes of GTVr, TG, TC1, TC2 and TE
were 29.33 cm3, 8.74 cm3, 7.08 cm3, 2.88 cm3 and
0.38 cm3, respectively.Table 2 Relationship between T classification at initial
diagnosis and at recurrence
Initial T
classification
No. patients by recurrent T classification Total
rT1 rT2 rT3 rT4
T1 2 2 2 0 6
T2 1 1 3 2 7
T3 2 0 5 6 13
T4 0 0 2 4 6
Total 5 3 12 12 32The topographic analysis of the local failure patterns
showed “central” in 16 patients (50.0%); “marginal” in 9
patients (28.1%); and “outside” in 7 patient (21.9%).
Factors that may influence the recurrence patterns
were analyzed, including the histological type at initial
diagnosis, stage of initial disease, dosimetric parameters
of initial IMRT plan, residue or no while initial treat-
ment finished and interval to recurrence. It revealed
only 2 significant factors: the volume of GTVnx and
CTV1. The median volumes of GTVnx were 45.84 cm3
in the central failure group, 29.44 cm3 in the marginal
failure group, and 21.52 cm3 in the outside failure group,
respectively (p = 0.012), and the median volumes of
CTV1 were 87.28 cm3, 61.90 cm3 and 58.74 cm3 in the
three groups, respectively (p = 0.033).
Discussion
IMRT is a highly conformal radiation technique enabling
delivery of high radiation doses to the gross tumor and
high-risk areas while sparing the adjacent organs. Since
the dose distribution is significant different between
IMRT and conventional RT, is there also some unique
quality with the failure patterns after IMRT? This study
summarized the experience through the local failed cases
in large number of patients with NPC, in hopes that the
application of IMRT can be further optimized.
In our patients, the majority had more advanced
T-stages at recurrence than that at initial diagnosis.
Nasopharynx and structures adjacent to it, such as the
parapharyngeal space and retropharyngeal space, the
probability of invasion could be observed to be signifi-
cantly lower at recurrence. Conversely, the probability of
invasion to the ethmoid sinus was significantly higher at
recurrence. As the definition of CTV required, the para-
pharyngeal space and retropharyngeal space are usually
inside the CTV1. The mean dose of CTV1 at initial
radiotherapy was about 70Gy in our patients, and the
Table 3 Comparison of tumor invasion in patients with pNPC and rNPC






No invasion in pNPC
and rNPC (case)
P-value
Nasopharynx 25 7 0 0 0.008
Oropharynx 3 3 2 24 0.655
Nasal cavity 6 1 6 19 0.059
Laryngopharynx 0 0 2 30 0.157
Soft palate 0 0 3 29 0.083
Parapharyngeal space 11 13 0 8 <0.001
Longus capitis 5 9 4 14 0.052
Retropharyngeal space 6 14 1 11 0.001
Skull base 15 4 4 9 1.000
Sphenoid sinus 3 5 7 17 0.564
Ethmoid sinus 1 0 8 23 0.005
Masticator space 1 3 3 25 1.000
Cavernous sinus 2 2 3 25 0.655
Intracranial 1 0 2 29 0.157
Abbreviations: pNPC primary nasopharyngeal carcinoma, rNPC recurrent nasopharyngeal carcinoma.
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speculate such a high dosage would devastate the nor-
mal structure of nasopharynx, with the local blood
supply reduced and unfavorable for tumor growth, and
the tumor relocates and occurs far away from the
nasopharynx.
The posterior ethmoid was included in the standard
two-dimensional(2-D) radiation fields [14], even patients
with T1/T2 stages, so relapse in the ethmoid sinus was
not common. However, IMRT can create a more con-
formal distribution around the targets, and the high-
dose region is defined by the precise three-dimensional
(3-D) sectional anatomy. So the CTV should be smaller
with IMRT. Physicians initially attempted to use IMRT
by creating CTV on the basis of past experiences with 2-
D planning, the law of local invasion and the radiological
information. There is no appreciable differences with
various definitions of CTV [11,15,16], and the rates of
locoregional control were similar and satisfied. But the
vast majority of these definitions did not mention if the
posterior ethmoid sinus should be included in the CTV.
The ethmoid sinus is the earliest developed of the
nasal sinus, and it tends to spread as far as there is
any compact bone, which leads to great variability with
the anatomical position of the posterior border of the
ethmoid sinus. It was reported that 66% of the poster-
ior ethmoid sinus intruded into the sphenoid body, 8%
intruded into the lesser wing of sphenoid bone, 38%
spreaded downward and resulted in middle turbinate
gasification [17]. Thus, the ethmoid sinus has a close
relation with the surrounding anatomic structures. A
larger sample study is expected to identify whether theposterior ethmoid sinus should be included in the
high-risk area.
In the local failure patterns after 3D-RT, a study retro-
spectively reviewed 151 patients with head-and-neck
cancer(HNC), 14 of whom developed local recurrences,
which showed 12 were in-field failure, 1 was marginal,
and 1 was out-of-field [18]. Since IMRT became rapidly
utilized in the treatment of HNC in the late 1990s, the
recurrent patterns of IMRT have been studied in limited
published literature. Chao et al. analyzed 126 HNC pa-
tients treated with IMRT delivered with radical intent
without surgery in 41% of patients, and post-operatively
in 59% of patients [19]. After a median follow up of
26 months, 17 recurrences were noted, of which 9 were
in-field, 3 were marginal failures and 5 were outside of
the IMRT field. Studer et al. reported 280 HNC patients
treated with IMRT, in 75% of whom definitive IMRT
was performed [20]. After a mean follow-up of 23.2 months,
46 local failures have been observed, 45 of which were
confirmed “in field”. Ng et al. reported the treatment
outcomes of 193 NPC patients with a median follow up
of 30 months [21]. There were 16 local failures, 13 of
that were considered in field.
In our series, local failure patterns were categorized
according to the relationship of recurrent tumors and
primary target volumes, which could evaluate the ration-
ality of target volume delineation in our institution more
effectively. The result demonstrated that approximately
80% of the recurrent tumors were located mainly inside
CTV, with the median mean dose of GTVr as 70.86Gy.
It seems that the delineation of target volumes are
reasonable, but why failures in the region originally
Figure 3 One patient with marginal failure. Part of primary tumor
was just inside CTV2 (blue line), but outside GTV or CTV1. The white
arrow indicates the recurrent tumor.
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analysis of factors that may influence the recurrence pat-
terns, it was found that the median volume of GTVnx
and CTV1 in the group “central failure” were signifi-
cantly larger than those in the other 2 groups. It is con-
cluded that the large size tumors might not be really
cured under the conventional radical dose. Shen et al.
reported 154 patients with NPC treated with accelerated
hyperfractionated radiotherapy [22]. The 5-year local
failure-free rate were 89.4% vs 48.9% (p = 0.002), respect-
ively, for patients whose GTV-P were ≤60 ml and
>60 ml. In a study with 290 NPC patients [23], PTV
>60 cc were associated with significantly poorer local
control (p < 0.001). In the early 1980s, Fletcher has pro-
posed that a certain tumor volume requires a certain ra-
diation dose so as to get a radical cure. Tumors about
3 cm3 should not be irradiated less than 75Gy, and the
larger ones even need more than 100Gy [24]. Therefore,
larger tumors require higher doses for their control. We
should design a more individual treatment plan to the
large tumors, raising the prescription dose in hopes of
“real cure”.
A previous study showed that tumors less than 1 mm
in diameter were well-oxygenated, and hypoxia would
occur when the tumors grew larger [25]. Hypoxic mam-
malian cells are 2.5 to 3 times less radiosensitive than
well-oxygenated cells. In vitro and in vivo measurements
have shown that an increased radiation dose may over-
come hypoxic resistance [26]. However, increasing the
radiation dose indiscriminately may increase normal tis-
sue complication rates. One approach is to implement
hypoxia imaging-guided IMRT for dose escalation. So
far, there were experimental application with 18F-FMI-
SO,18F-FAZA and 62Cu-ATSM PET to guide IMRT
planning on a small scale [27-29]. Another potential ap-
proach is to develop oxygen-mimetic, electron-affinic
radiosensitizers. These radiosensitizers are easier to ad-
minister than oxygen, less rapidly metabolized, and can
therefore diffuse further from blood vessels into the hyp-
oxic regions of the tumor. Toxicity has somewhat lim-
ited their use, but there was evidence of clinical efficacy
[30,31].
In present study, there were 9 “marginal failure” and 7
“outside the field”, all of which the primary tumor ex-
tents and initial IMRT plans were reappraised. It was
found that defects in target volume delineation in 4
cases. Among them, 2 primary tumors had invaded to
the oropharynx and parapharyngeal space, but they were
not completely included in GTV, which led to relapse in
oropharynx and laryngopharynx (Figure 3). The other
two patients with clivus or sphenoid bone invaded at ini-
tial diagnosis, but they were not well included in GTV,
which led to recurrences in skull base and the ethmoid
sinus. The high conformity and steep dose gradientswith IMRT have made the accurate target volume delin-
eation of outmost importance. Any fault or carelessness
in delineation can result in overdose of the critical struc-
ture or escape of the target volume. Some measures can
be adopted to improve the accuracy of target volume de-
lineation, including establishment of guidelines for target
volume delineation, obtaining high-quality image (using
image fusion technology if necessary) and organizing
consultations with radiologists.
There is no physiological activity like peristalsis or
aspiratory movement that can cause significant anatomic
changes in the nasopharynx nearby, but shrinking of the
primary tumor or nodal masses, body weight loss and
set-up error during fractionated RT may lead to changes
in body contour, target volumes and risk organs. They
would affect the dose distribution and can be the root of
marginal recurrence. It was reported that patients with
NPC or with great weight loss or reduction in neck sep-
aration did have clinically significant benefits with adap-
tive RT using helical tomotherapy [32]. We hope the
benefits would eventually bring improvement in local
control rate.Conclusions
Our study investigated the local failure patterns of NPC
patients treated with IMRT in a large cohort. Based on
our results, the recurrent tumors had their unique
character and regularity of invasion to adjacent struc-
tures. “Central” failure was the major local failure
pattern. The volumes of GTVnx and CTV1 were sig-
nificantly correlated with recurrent patterns. Identify
the tumor cells which will be insensitive to RT and
employ more aggressive and target-specific therapeutic
approaches may be an effective way to reduce the cen-
tral failure.
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